Français
ItalianoBond AbbVie 2.6% ( US00287YBZ16 ) in USD
| Issuer | AbbVie | ||||||||||||||
| Market price | 99.755 % ▲ | ||||||||||||||
| Country |  United States
|
||||||||||||||
| ISIN code |
 US00287YBZ16 ( in USD )
|
||||||||||||||
| Interest rate | 2.6% per year ( payment 2 times a year) | ||||||||||||||
| Maturity | 11/21/2024 - Bond has expired | ||||||||||||||
| Minimal amount | 2 000 USD | ||||||||||||||
| Total amount | 3 739 140 000 USD | ||||||||||||||
| Cusip | 00287YBZ1 | ||||||||||||||
| Standard & Poor's ( S&P ) rating | A- ( Upper medium grade - Investment-grade ) | ||||||||||||||
| Moody's rating | A3 ( Upper medium grade - Investment-grade ) | ||||||||||||||
| Detailed description |
AbbVie is a research-based biopharmaceutical company focused on developing and marketing innovative therapies in several key therapeutic areas including immunology, oncology, neuroscience, and ophthalmology. The Bond issued by AbbVie ( United States ) , in USD, with the ISIN code US00287YBZ16, pays a coupon of 2.6% per year. The coupons are paid 2 times per year and the Bond maturity is 11/21/2024 The Bond issued by AbbVie ( United States ) , in USD, with the ISIN code US00287YBZ16, was rated A3 ( Upper medium grade - Investment-grade ) by Moody's credit rating agency. The Bond issued by AbbVie ( United States ) , in USD, with the ISIN code US00287YBZ16, was rated A- ( Upper medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency. |
||||||||||||||
| |||||||||||||||